Epizyme to Participate in Upcoming Healthcare Conferences in March
02 Mars 2022 - 2:00PM
Business Wire
Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage
biopharmaceutical company developing and delivering transformative
therapies against novel epigenetic targets, today announced its
participation in two investor conferences in March.
Cowen 42nd Annual Health Care Conference Shefali Agarwal,
Chief Medical Officer, will participate in the Cowen 42nd Annual
Health Care Conference as part of the Targeted Oncology panel.
Tuesday, March 8, at 9:10am EST
Barclays Global Healthcare Conference Grant Bogle, Chief
Executive Officer, will participate in a fireside chat at the
Barclays Global Healthcare Conference. Tuesday, March 15, 2022, at
2:05pm EST
Live webcasts of the presentations will be available under the
investor section of the Company’s website at
www.epizyme.com, and will be archived
for 60 days following the event.
About Epizyme, Inc.
Epizyme, Inc. is a fully integrated, commercial-stage
biopharmaceutical company committed to its mission of rewriting
treatment for cancer through novel epigenetic medicines. The
Company is focused on creating medicines that are targeted at
specific causes of diseases, that are orally administered,
tolerable, easy to take and based on a deep understanding of the
patients that may benefit from them. The Company aspires to change
the standard-of-care for patients and physicians by developing
medicines with fundamentally new mechanisms of action. For more
information, visit www.epizyme.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220228005306/en/
Media: Erin Graves media@epizyme.com (617) 500-0615
Investors: Caitlin Stern cstern@realchemistry.com
Epizyme (NASDAQ:EPZM)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Epizyme (NASDAQ:EPZM)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Epizyme Inc (NASDAQ): 0 recent articles
Plus d'articles sur Epizyme, Inc.